Editorial: mesalamine and mucosal microbiome in quiescent ulcerative colitis-what can we learn? Authors' reply

Maya Olaisen^{1

2}, Reidar Fossmark^{1

2}

Affiliations

¹ Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU - Norwegian University of Science and Technology, Trondheim, Norway.
² Department of Gastroenterology, Clinic of Medicine, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.

Editorial

Maya Olaisen et al. Aliment Pharmacol Ther. 2019 Jun.

. 2019 Jun;49(12):1532.

doi: 10.1111/apt.15285.

Maya Olaisen^{1

2}, Reidar Fossmark^{1

2}

¹ Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU - Norwegian University of Science and Technology, Trondheim, Norway.
² Department of Gastroenterology, Clinic of Medicine, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.

No abstract available

Comment on

Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis.
Olaisen M, Spigset O, Flatberg A, Granlund AVB, Brede WR, Albrektsen G, Røyset ES, Gilde B, Sandvik AK, Martinsen TC, Fossmark R. Olaisen M, et al. Aliment Pharmacol Ther. 2019 May;49(10):1301-1313. doi: 10.1111/apt.15227. Epub 2019 Mar 20. Aliment Pharmacol Ther. 2019. PMID: 30895635 Free PMC article.
Editorial: mesalazine and mucosal microbiome in quiescent ulcerative colitis-what can we learn?
Buchner AM, Lichtenstein GR. Buchner AM, et al. Aliment Pharmacol Ther. 2019 Jun;49(12):1531. doi: 10.1111/apt.15281. Aliment Pharmacol Ther. 2019. PMID: 31134651 No abstract available.